Related Experiment Video

Updated: May 12, 2026

Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome
07:23

Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome

Published on: June 15, 2016

[Small interfering RNA targeting STAT3 enhances antitumor activity of doxorubicin]

Tian-Xiao Wang1, Ying-Ying Wang, Zhong-Qing Zhang

  • 1Institute of Chinese Materia Medica, College of Pharmacy, Henan University, Kaifeng 475004, China. wtx1975@126.com

Yao Xue Xue Bao = Acta Pharmaceutica Sinica
|April 23, 2013
PubMed

Insights

Small interfering RNA targeting STAT3 (STAT3-siRNA) enhances doxorubicin's antitumor activity by reducing STAT3 expression and increasing drug accumulation. This combination therapy boosts doxorubicin-induced apoptosis in cancer cells.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Pharmacology

Context:

  • Signal transducer and activator of transcription 3 (STAT3) is frequently overexpressed in various cancers, contributing to tumor growth and drug resistance.
  • Doxorubicin is a widely used chemotherapy agent, but its efficacy can be limited by resistance mechanisms.
  • STAT3 signaling plays a role in cellular resistance to chemotherapy, including doxorubicin.

Purpose:

  • To investigate the synergistic effect of STAT3-siRNA and doxorubicin on cancer cells.
  • To evaluate how STAT3-siRNA affects doxorubicin uptake and apoptosis.
  • To determine if STAT3 inhibition can overcome doxorubicin resistance.

Summary:

  • STAT3-siRNA effectively reduced STAT3 mRNA and protein expression in HepG2, HeLa, and K562/DOX cells.
  • Combined treatment with STAT3-siRNA and doxorubicin significantly decreased the IC50 values compared to doxorubicin alone.
  • STAT3-siRNA enhanced intracellular doxorubicin accumulation and promoted doxorubicin-induced apoptosis in the tested cancer cell lines.

Impact:

  • STAT3-siRNA demonstrates potential as an adjuvant therapy to enhance the efficacy of doxorubicin in cancer treatment.
  • This approach may offer a strategy to overcome or circumvent chemotherapy resistance.
  • Further research could explore the clinical translation of STAT3-targeted therapies in combination with conventional chemotherapeutics.

More Related Videos

Using In Vitro Live-cell Imaging to Explore Chemotherapeutics Delivered by Lipid-based Nanoparticles10:26

Using In Vitro Live-cell Imaging to Explore Chemotherapeutics Delivered by Lipid-based Nanoparticles

Published on: November 1, 2017

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts11:19

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts

Published on: October 9, 2016

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...